Gustavo A. Rosario Benitez

Array ( [id] => 9191028 [patent_doc_number] => 20130330343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/714238 [patent_app_country] => US [patent_app_date] => 2012-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 59386 [patent_no_of_claims] => 138 [patent_no_of_ind_claims] => 65 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13714238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8815122 [patent_doc_number] => 20130116167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'ANTI-MART-1 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/667036 [patent_app_country] => US [patent_app_date] => 2012-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 22000 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13667036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10136011 [patent_doc_number] => 09169324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-27 [patent_title] => 'Reducer of immunosuppression by tumor cell and antitumor agent using the same' [patent_app_type] => utility [patent_app_number] => 13/627655 [patent_app_country] => US [patent_app_date] => 2012-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 27 [patent_no_of_words] => 15423 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13627655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12565995 [patent_doc_number] => 10017573 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Anti-abTCR antibody [patent_app_type] => utility [patent_app_number] => 14/241099 [patent_app_country] => US [patent_app_date] => 2012-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 13097 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14241099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10975354 [patent_doc_number] => 20140378389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE' [patent_app_type] => utility [patent_app_number] => 14/344354 [patent_app_country] => US [patent_app_date] => 2012-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 17099 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14344354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8606083 [patent_doc_number] => 20130011395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-10 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS' [patent_app_type] => utility [patent_app_number] => 13/588684 [patent_app_country] => US [patent_app_date] => 2012-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18228 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13588684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8828684 [patent_doc_number] => 20130129729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'COMPOSITIONS COMPRISING CROSS-SPECIES-SPECIFIC ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/567672 [patent_app_country] => US [patent_app_date] => 2012-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 32672 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13567672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9184080 [patent_doc_number] => 08624013 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-07 [patent_title] => 'Interleukin-10 antibodies' [patent_app_type] => utility [patent_app_number] => 13/553554 [patent_app_country] => US [patent_app_date] => 2012-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 8 [patent_no_of_words] => 21913 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13553554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8659022 [patent_doc_number] => 20130039850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-14 [patent_title] => 'HETEROLOGOUS ANTIBODIES WHICH BIND HUMAN CD4' [patent_app_type] => utility [patent_app_number] => 13/544012 [patent_app_country] => US [patent_app_date] => 2012-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 99 [patent_figures_cnt] => 99 [patent_no_of_words] => 85058 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13544012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9227353 [patent_doc_number] => 08633020 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-21 [patent_title] => 'Allorestricted peptide-specific T cells' [patent_app_type] => utility [patent_app_number] => 13/544226 [patent_app_country] => US [patent_app_date] => 2012-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 5696 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13544226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11429258 [patent_doc_number] => 09567566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-14 [patent_title] => 'HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants' [patent_app_type] => utility [patent_app_number] => 13/533492 [patent_app_country] => US [patent_app_date] => 2012-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 11263 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13533492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8637100 [patent_doc_number] => 20130028903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-31 [patent_title] => 'PURIFIED ANTIBODY COMPOSITION' [patent_app_type] => utility [patent_app_number] => 13/532511 [patent_app_country] => US [patent_app_date] => 2012-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 64042 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13532511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8585686 [patent_doc_number] => 20130004507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-03 [patent_title] => 'METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/530363 [patent_app_country] => US [patent_app_date] => 2012-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 17321 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13530363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9537155 [patent_doc_number] => 20140161802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-12 [patent_title] => 'SELECTIVE ELIMINATION OF EROSIVE CELLS' [patent_app_type] => utility [patent_app_number] => 14/124876 [patent_app_country] => US [patent_app_date] => 2012-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 20403 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14124876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635687 [patent_doc_number] => 09353181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Human anti-IL-23 antibodies, compositions, methods and uses' [patent_app_type] => utility [patent_app_number] => 13/524122 [patent_app_country] => US [patent_app_date] => 2012-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 27 [patent_no_of_words] => 39473 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13524122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9490614 [patent_doc_number] => 20140141020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'ANTI-CD3 THERAPIES' [patent_app_type] => utility [patent_app_number] => 14/126334 [patent_app_country] => US [patent_app_date] => 2012-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 10314 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14126334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405437 [patent_doc_number] => 20120237500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'SCD Fingerprints' [patent_app_type] => utility [patent_app_number] => 13/482432 [patent_app_country] => US [patent_app_date] => 2012-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 42764 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13482432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9408089 [patent_doc_number] => 20140099341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-10 [patent_title] => 'Modulated Immunodominance Therapy' [patent_app_type] => utility [patent_app_number] => 14/122036 [patent_app_country] => US [patent_app_date] => 2012-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 16424 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14122036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9477257 [patent_doc_number] => 20140134720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-15 [patent_title] => 'METHOD' [patent_app_type] => utility [patent_app_number] => 14/117947 [patent_app_country] => US [patent_app_date] => 2012-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9100 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14117947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11480490 [patent_doc_number] => 09587021 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'CD3-binding molecules capable of binding to human and non-human CD3' [patent_app_type] => utility [patent_app_number] => 14/118523 [patent_app_country] => US [patent_app_date] => 2012-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 36 [patent_no_of_words] => 39913 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14118523 [rel_patent_id] =>[rel_patent_doc_number] =>)